TOKISAKE-ASSOCIATION
20.11.2020 11:32:10 CET | Business Wire | Press release
The Tokisake Association (located in Kyoto Prefecture, President, Tokubee Masuda) was established in August 2019 with the aim of reviving the culture of aged sake and establishing and further enhancing the value of sake to the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201120005313/en/
The company will sell the highest-priced product in the history of Japanese sake, “Toki no Shirabe” in a limited edition of 20 sets of 8 bottles (720 ml) for 2,020,000 yen, for domestic and international customers to commemorate the establishment of the Association.
In addition to seven bottles of secret sake commercialized from each of the seven breweries that are the founding members of the Association, another very rare bottle is an assemblage (blend) by the world-renowned sommelier Mr. Shinya Tasaki, to complete a limited edition of eight bottles.
By releasing this ultra-gorgeous new product, which is a collection of excellent products engraved over the years, they will continue to contribute to the creation of even more value for Japanese sake in Japan and abroad.
[New Product Overview]
Product Name: [Special Limited] Aged sake set of 8 bottles of "Toki no Shirabe"
Price: 2.02 million yen
Booking period: November 24 (Tuesday) to December 5 (Saturday)
Pre-orders are accepted at: Shusaron.com (https://shusaron-online.com/shopdetail/000000000042/
).
If the number of reservation requests exceeds 20, eligible purchasers will be selected by lottery. The set’s gift box is an original work of art by Yoshizawa Ryoichi, an artisan, and is “made of rice husks that are removed during the brewing process and finished with lacquer based on the shape of a traditional Japanese stacked box,” according to Yoshizawa.
[Limited release 8 bottles of sake]
- Masuda Tokubee Shoten Co., Ltd. / Kyoto: “Tsukino Katsura” 1999
- Kokuryu Sake Brewing Corporation / Fukui: Kokuryu "Muni" Junmai Daiginjo Genshu 1996
- DEWAZAKURA SAKE BREWERY CO.,LTD / Yamagata: "Dewazakura Daiginjo Daikoshu cold aged” 1990 & 1986
- Nanbu Bijin Co., Ltd. / Iwate: "Nanbu Bijin All Koji" Junmai 1998
- Shimazaki Shuzo Co., Ltd. / Tochigi: "Azumarikishi Uroko" Daiginjo Genshu 1987
- NAGAI SAKE INC. / Gunma: “Mizubasho Shizuku Daiginjo ice aged" 2003
- Kidoizumi Shuzo Co., Ltd. / Chiba: "Kidoizumi Afs" Yamahai Junmai 1984
- Mr. Shinya Tasaki's assemblage blend, "Toki no Shirabe”
https://www.youtube.com/watch?v=B18SYRjMA8c
View source version on businesswire.com: https://www.businesswire.com/news/home/20201120005313/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Inspirit Capital to Acquire Kaplan Languages Group20.4.2026 17:15:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, is pleased to announce its plans to acquire KLG Kaplan Languages Group (“KLG”), a leading global language education platform, from Kaplan. All conditions for the sale have been met, and completion is due to take place on 1 May. KLG comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Since 2006, KLG has provided high-quality language education, supporting students in achieving their language goals through academic excellence, cultural immersion, and life-changing experiences. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. This next phase of ownership will also see the development of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. Paul Youens, Investment Director, Inspirit Capital: “KLG has built a st
Cleaner by Design: SaniSure Introduces PETG PharmaTainer™ Ultra-Clean Bottles & Carboys20.4.2026 16:00:00 CEST | Press release
Industry’s most widely adopted PETG material meets industry-leading cleanliness, compliance, and RNase/DNase-free validation—now available across the full bioprocessing workflow. SaniSure® today announced the launch of PETG PharmaTainer™, a new line of bioprocessing bottles and carboys combining widely accepted, medical-grade Eastman Eastar® PETG 6763 resin (DMF#9987) with SaniSure’s proprietary process and advanced automation. This launch expands SaniSure’s established PharmaTainer® platform—extending its proven cleanliness, robustness, and performance attributes to include industry-standard PETG alongside its existing PET and PC offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420641769/en/ PETG PharmaTainer™ bottles and carboys—RNase/DNase-free, ultra-clean, ready-to-use containers for bioprocessing applications. Available in volumes from 10 mL stability vials to 10 L carboys — in sterile (gamma-irradiated) an
Leaders of Dubai-Based Unicorns Hail City as Global Innovation Hub Shaping Future Technology and Driving the Digital Economy20.4.2026 15:08:00 CEST | Press release
Leaders of Dubai-based unicorn companies have reaffirmed the emirate’s status as a global hub for digital innovation and technology-led growth. The senior executives highlighted Dubai’s forward-looking regulatory environment, advanced infrastructure, and ability to attract international talent as key factors strengthening its appeal for high-growth digital businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420503062/en/ Leaders of Dubai-based unicorns hail city as global innovation hub shaping future technology and driving the digital economy (Photo: AETOSWire) They noted that Dubai has evolved into a strategic launchpad for ambitious companies, offering an agile business environment that supports innovation and enables expansion into regional and international markets. The business leaders also praised the strong alignment between the public and private sectors within Dubai’s digital ecosystem, supported by Dubai
Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 15:00:00 CEST | Press release
– Highly innovative and original gameplay earns strong reception from players around the globe – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broade
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom